Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Active not recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 4Sarcoma 2Lymphoid 2Genitourinary 2Gastrointestinal 2Breast 2Thoracic 1Other hematologic neoplasm 1Head & Neck 1Dermatologic 1

Conditions

Urinary Bladder Neoplasms 157Carcinoma, Transitional Cell 56Non-Muscle Invasive Bladder Neoplasms 30Urethral Neoplasms 24Carcinoma, Renal Cell 23Neoplasms 19Kidney Neoplasms 15Pancreatic Neoplasms 14Ovarian Neoplasms 14Neoplasm Metastasis 13Carcinoma, Non-Small-Cell Lung 13Prostatic Neoplasms 12Ureteral Neoplasms 11Urologic Neoplasms 9Colorectal Neoplasms 9Breast Neoplasms 9Lung Neoplasms 7Testicular Neoplasms 6Stomach Neoplasms 6Melanoma 6Sarcoma 5Urothelial Cancer 4Squamous Cell Carcinoma of Head and Neck 4Small Cell Lung Carcinoma 4Osteosarcoma 4Colonic Neoplasms 4Urogenital Neoplasms 3Triple Negative Breast Neoplasms 3Recurrence 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3

Interventions

Magnetic Resonance Spectroscopy 10X-Rays 7Specimen Handling 7Phantoms, Imaging 6Nuclear Medicine Department, Hospital 6Biopsy 6ulixertinib 3palbociclib 3larotrectinib 3erdafitinib 3Temozolomide 3tipifarnib 2tazemetostat 2selpercatinib 2olaparib 2ivosidenib 2ensartinib 2Vemurafenib 2Thalidomide 2Paclitaxel 2Nivolumab 2LY3023414 2Gemcitabine 2Erlotinib Hydrochloride 2Cisplatin 2Carboplatin 2trastuzumab deruxtecan 1trastuzumab biosimilar HLX02 1trametinib 1sapanisertib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Glioma × Gemcitabine × Genitourinary × Clear all
NCT04521686 2026-04-22

Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations

Eli Lilly and Company

Phase 1 Active not recruiting
200 enrolled
BreastCNSDermatologicGastrointestinalGenitourinaryHead & NeckSarcoma

Breast Neoplasms, Chondrosarcoma, Colonic Neoplasms, Glioblastoma, Glioma, Melanoma, Prostatic Neoplasms, Thyroid Neoplasms, Central Nervous System Neoplasms, Cholangiocarcinoma

NCT03678883 2026-04-03

9-ING-41 in Patients With Advanced Cancers

Actuate Therapeutics Inc.

Phase 2 Active not recruiting
350 enrolled
BreastCNSGastrointestinalGenitourinaryLymphoidOther hematologic neoplasmSarcomaThoracic

Bone Neoplasms, Breast Neoplasms, Glioma, Kidney Neoplasms, Lung Neoplasms, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Pancreatic Neoplasms, Sarcoma, Colorectal Neoplasms, Leukemia-Lymphoma, Adult T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡